Literature review of data-based models for identification of factors associated with racial disparities in breast cancer mortality

Abstract

In the United States, early detection methods have contributed to the reduction of overall breast cancer mortality but this pattern has not been observed uniformly across all racial groups. A vast body of research literature shows a set of health care, socioeconomic , biological, physical, and behavioural factors influencing the mortality disparity. In this paper, we review the modelling frameworks, statistical tests, and databases used in understanding influential factors, and we discuss the factors documented in the modelling literature. Our findings suggest that disparities research relies on conventional modelling and statistical tools for quantitative analysis, and there exist opportunities to implement data-based modelling frameworks for (1) exploring mechanisms triggering disparities, (2) increasing the collection of behavioural data, and (3) monitoring factors associated with the mortality disparity across time.

Atractylenolide‐1 affects glycolysis/gluconeogenesis by downregulating the expression of TPI1 and GPI to inhibit the proliferation and invasion of human triple‐negative breast cancer cells

“…Data show that there were 2.1 million new cases of breast cancer worldwide in 2018, with approximately 50,000 deaths per year, with around 20% of breast cancers being triple‐negative breast cancer (TNBC). The survival rate of TNBC patients is reported to be worse than that of non‐TNBC patients (Prieto et al, 2019). Due to the lack of reliable molecular drug targets, the treatment of TNBC is limited to conventional chemotherapy (Fischer, 2019; Harnan et al, 2019).…”

Resultado oncológico de cirugía conservadora con adyuvancia en cáncer de mama, Hospital San Felipe, Tegucigalpa

“…Los estudios realizados son muy consistentes identificando que el retraso o pobre calidad de los sistemas de salud, alta privación de recursos y mal estado físico de los pacientes, así como tumor en estadios avanzados, se han asociado a disparidades raciales que afectan la mortalidad por cáncer de mama. 2 El sistema de estadificación más utilizado es el propuesto por la American Joint Committee on Cancer (AJCC), el sistema TNM, que incluye el tamaño tumoral, la invasión a ganglios linfáticos regionales y la presencia de metástasis. [3][4][5] El cáncer de mama estadio temprano I y II, se define como enfermedad confinada a la mama con o sin ganglios linfáticos regionales, en ausencia de metástasis a distancia.…”